Additionally, enzalutamide, a competitive inhibitor of AR, shows clinical benefit in PCa patients initially until resistance develops, however, enzalutamide treatment showed no clinical benefit in HCC patients [26,45]. Here, AR is linked to hepatocellular carcinoma.